TELA Bio, Inc.

I would now like to turn the conference call over to Louisa Smith. Thank you, Martin. Please go ahead.

Thank you, Kelvin, and good afternoon, everyone. Earlier today, Telebio released financial results for the third quarter of 2025. A copy of the press release is available on the company's website. Joining me on today's call are Tony Koblish, Chief Executive Officer, Jeff Blizzard, President, and Roberto Cuca, Chief Operating Officer and Chief Financial Officer. Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's annual report on Form 10-K and quarterly reports on Form 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development and pipeline opportunities, product potential, the impact of various macroeconomic conditions identified in our filings, like changes in surgical procedural volumes, the regulatory environment, sales and marketing strategies, capital resources, or operating performance. With that, I'll now turn the call over to Tony.

Thank you, Louisa, and good afternoon. Thank you for joining Telebio's third quarter 2025 earnings call. Q3 25 marked another important step forward in Telebio as we continue to execute on expanding our commercial footprint, improving our operating discipline, and strengthening our patient-centric culture. We reported revenue of 20.7 million for the quarter, representing 9% growth over the prior year. Growth was fueled by stronger adoption across our existing customer base and augmented by the addition of new accounts. This reflects growing demand for our Ovitex reinforced tissue matrix and Ovitex PRS portfolios and contributions from our expanding commercial presence in Europe. International sales grew 9% over the prior period. driven by increased traction in the UK and early progress from the commercial launch of the Ovitex IHR in Europe. Over the last few months, we have placed deliberate focus on strengthening our operational foundation. We invested in our sales organization from which we expect stronger commercial performance going forward. We continue to demonstrate financial prudence in our sales and marketing spends, which improved as a percentage of revenue from 89.7% in Q1 to 83.5% in Q2 and further to 73.6% in Q3. Additionally, we have strengthened the capabilities and expertise of our board to provide valuable strategic insights through our next phase of growth. And finally, as announced this evening, we have reinforced our balance sheet to eliminate any concerns around financing and allow us to focus squarely on execution and growth. With these foundational elements now in place, we're poised to re-excel under the right leadership and the right playbook. Before turning the call over to Jeff to review upgrades in the commercial organization, I'd like to point out some key highlights and milestones we reached in the third quarter that detail TELA's expanding presence in the soft tissue restoration market. As mentioned on our last call at the American Society of Plastic Surgeons, Plastic Surgery The Meeting, Ovitex PRS was featured in three scientific abstract publications. These presentations contributed to a growing and meaningful body of clinical evidence. Now more than 50 published or presented works on Ovitex and 10 on Ovitex PRS, representing over 1,100 patients in peer-reviewed publications and ongoing data collection in more than 2,500 patients. I'm also pleased to share that two sites have now been activated and the first patient has been enrolled in our hiatal study, evaluating clinical hiatal hernia outcomes using Ovitex or ECHO. Together, these milestones reflect the continued expansion of our real-world data, which strengthens surgeons' confidence and support and broader adoption and reinforces the clinical validity of our technology. In the third quarter, we achieved a significant commercial milestone, surpassing 100,000 implantations of Ovitex and Ovitex PRS combined globally. This achievement further underscores our growing impact and continued progress across the soft tissue repair and reconstruction markets. We continue to expand our market presence both in the U.S. and abroad. In Europe, we advanced awareness through the targeted surgeon engagement, including a July cadaver lab with 30 key surgeons. and made meaningful progress with the UK NHS value-based procurement initiative, securing NHS finance sign-off in September. In the U.S., we further strengthened our national reach through new and expanded contracts that made our portfolio available across a diverse range of health systems, from some of the nation's largest and most innovative networks to community hospitals, broadening our market access in the quarter by an additional 835 hospitals. We recently announced two additions to our board of directors, welcoming Betty Jo Rocio and Bill Plavonic. Betty Jo will provide critical insights into our market access strategy, given her decades of experience in advancing clinical excellence and supply chain optimization at large healthcare systems and group purchasing organizations. We are also fortunate to have Bill on board. as an investor combined with his direct experience running publicly held medtech companies will help drive long-term shareholder value and enhance communication with our investors. I would now like to turn the call over to Jeff, who transitioned from our board to serve as president in June. Since that time, he has been instrumental in refining our commercial strategy and building a more patient and results-focused culture within our sales organization. Jeff brings the exact combination of operational expertise and strategic vision needed for this moment. He will provide commentary on our third quarter and our optimism for the future. Jeff.